PTC Therapeutics (NASDAQ:PTCT) Cut to “Hold” at Wall Street Zen

PTC Therapeutics (NASDAQ:PTCT) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group increased their price objective on shares of PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a report on Wednesday, November 5th. Royal Bank Of Canada dropped their target price on shares of PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating for the company in a research report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Bank of America decreased their price objective on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday. Finally, Barclays upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $68.00 to $119.00 in a report on Tuesday, January 27th. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, PTC Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $80.73.

PTC Therapeutics Stock Up 1.1%

PTCT stock opened at $70.66 on Friday. PTC Therapeutics has a twelve month low of $35.95 and a twelve month high of $87.50. The company has a market cap of $5.67 billion, a P/E ratio of 9.13 and a beta of 0.48. The business has a fifty day moving average of $74.91 and a 200-day moving average of $67.91.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 373.67% and a net margin of 39.44%.The firm had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. During the same quarter in the previous year, the business earned ($0.85) earnings per share. PTC Therapeutics’s revenue for the quarter was down 22.7% compared to the same quarter last year. As a group, equities research analysts anticipate that PTC Therapeutics will post -4.52 earnings per share for the current fiscal year.

Insider Transactions at PTC Therapeutics

In other news, insider Eric Pauwels sold 40,290 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $75.43, for a total transaction of $3,039,074.70. Following the completion of the sale, the insider owned 70,373 shares of the company’s stock, valued at $5,308,235.39. This represents a 36.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Neil Gregory Almstead sold 71,928 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $83.44, for a total transaction of $6,001,672.32. Following the completion of the transaction, the insider directly owned 100,625 shares of the company’s stock, valued at approximately $8,396,150. The trade was a 41.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 298,246 shares of company stock valued at $23,393,870. 5.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On PTC Therapeutics

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of PTC Therapeutics by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock worth $668,691,000 after acquiring an additional 514,204 shares in the last quarter. Wellington Management Group LLP grew its position in PTC Therapeutics by 4.8% in the third quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock valued at $301,856,000 after purchasing an additional 224,481 shares in the last quarter. Janus Henderson Group PLC lifted its position in PTC Therapeutics by 28.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock worth $368,587,000 after buying an additional 1,077,776 shares in the last quarter. State Street Corp boosted its stake in shares of PTC Therapeutics by 34.2% during the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock worth $319,497,000 after buying an additional 1,071,343 shares during the last quarter. Finally, Toronto Dominion Bank boosted its stake in shares of PTC Therapeutics by 27.5% during the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after buying an additional 891,690 shares during the last quarter.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.